Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
conjunctivitis
Biotech
With FDA rejection for eye drug, Aldeyra plans speedy new trial
Aldeyra Therapeutics had prepared for the worst and now it's here. The FDA has rejected the dry eye drug reproxalap.
Annalee Armstrong
Nov 28, 2023 4:30am
Aldeyra's dry eye disease drug scores phase 3 conjunctivitis win
Jun 15, 2023 9:30am
Eton Pharma dips as FDA rejects its conjunctivitis med
Jul 15, 2019 9:52am
Realm scraps eye drug after midphase flop, sinking stock
Mar 12, 2018 9:00am
Anti-inflammatory biotech Aldeyra teams up with Janssen
Feb 27, 2018 9:58am
Tiny Aldeyra’s eye drug misses primary endpoint in phase 2
Jun 14, 2017 7:45am